
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$60.85
−$0.51 · -0.83%
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Latest quote
$60.85
−$0.51 · -0.83%
Regular session · ET · Market data may be delayed.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
75
Undervalued
Sentiment
68
Bullish
Risk
34
Moderate Risk
Momentum
70
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 79.95M USD | 39.01M USD | 31.64M USD | 21.25M USD | 21.83M USD |
| Cost of goods sold | 37.21M USD | 15.6M USD | 10.58M USD | 6.93M USD | 2.62M USD |
| Gross profit | 42.74M USD | 23.41M USD | 21.06M USD | 14.32M USD | 19.21M USD |
| Research and development | 7.77M USD | 3.26M USD | 3.32M USD | 4M USD | 6.24M USD |
| Selling, general, and administrative | 35.82M USD | 22.75M USD | 18.93M USD | 18.58M USD | 14.47M USD |
| Operating expenses | 42.67M USD | 26.01M USD | 22.25M USD | 22.58M USD | 20.7M USD |
| Interest expense | 4.78M USD | 2.01M USD | 1.06M USD | 955K USD | 1.04M USD |
| Depreciation and amortization | 4.04M USD | 1.15M USD | 901K USD | 1.77M USD | 462K USD |
| Operating income | 72K USD | −2.6M USD | −1.19M USD | −8.26M USD | −1.5M USD |
| Net income | −4.6M USD | −3.82M USD | −936K USD | −9.02M USD | −1.96M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$72.00
18.32% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM43.69M0.06%71.54B USD0.19%$256.61-2.88%
Vanguard Morningstar Total Stock Market ETFVTI35.76M0.00%689.3B USD0.03%$340.02-3.52%
Vanguard Extended Market ETFVXF16.11M0.02%30.2B USD0.05%$211.44-3.21%
iShares Russell 2000 Growth ETFIWO15.54M0.12%12.73B USD0.24%$320.43-3.57%
State Street SPDR S&P Pharmaceuticals ETFXPH11.23M2.24%501.19M USD0.35%$62.15-2.00%
First Trust Small Cap Growth AlphaDEX FundFYC10.45M0.83%1.26B USD0.70%$103.45-3.18%
Schwab U.S. Small-Cap ETFSCHA8.63M0.04%20.45B USD0.03%$30.51-2.83%
Vanguard Russell 2000 ETFVTWO8.19M0.05%16.8B USD0.06%$103.76-2.76%
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
State Street SPDR S&P Pharmaceuticals ETFXPH
First Trust Small Cap Growth AlphaDEX FundFYC
Schwab U.S. Small-Cap ETFSCHA
Vanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.